Your browser doesn't support javascript.
[Diabetes and COVID-19]. / Diabète et COVID-19.
Bouhanick, Béatrice; Cracowski, Jean-Luc; Faillie, Jean-Luc.
  • Bouhanick B; Pôle cardiovasculaire et métabolique, service d'HTA et de thérapeutique, CHU Rangueil, TSA 50032, 1, avenue J.- Poulhes, 31059 Toulouse cedex 9, France; UMR 1027, université Toulouse III, 31000 Toulouse, France. Electronic address: duly-bouhanick.b@chu-toulouse.fr.
  • Cracowski JL; Centre régional de pharmacovigilance de Grenoble, université Grenoble Alpes, CHU Grenoble, 38000 Grenoble, France. Electronic address: JLCracowski@chu-grenoble.fr.
  • Faillie JL; Département de pharmacologie médicale et toxicologie, Centre régional de pharmacovigilance Occitanie-Est, CHU Montpellier, 371, avenue du Doyen Gaston Giraud, 34295 Montpellier, France. Electronic address: jean-luc.faillie@umontpellier.fr.
Therapie ; 2020 Apr 23.
Article in French | MEDLINE | ID: covidwho-1221032
ABSTRACT
According to previous reports, diabetes seems to be associated with serious clinical events due to COVID-19. But is diabetes per se a risk factor of being infected by the virus? We discuss these points. Data about the antidiabetic drugs are scarce. Dipeptidylpeptidase-4 (DPP-4) is found as both a cell surface protein ubiquitously expressed in many tissues and as a soluble molecule found in serum/plasma, fluids. DPP-4 is involved in infection of cells by some viruses. We relate data about the use of DPP-4 inhibitors in diabetic patients. We conclude relating French and international recommendations in people with diabetes.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: French Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: French Year: 2020 Document Type: Article